Evidence map›Paper›PMID 36048828›Full record

ArticlePloS one2022

Alkaline ceramidase catalyzes the hydrolysis of ceramides via a catalytic mechanism shared by Zn2+-dependent amidases.

Jae Kyo Yi, Ruijuan Xu, Lina M Obeid, Yusuf A Hannun, Michael V Airola, Cungui Mao

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. PAQR4 oncogene: a novel target for cancer therapy.Medical oncology (Northwood, London, England) · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jae Kyo YiDepartment of Medicine, Stony Brook University, Stony Brook, NY, United States of America.ORCID 0000-0001-7053-601X
Ruijuan XuDepartment of Medicine, Stony Brook University, Stony Brook, NY, United States of America.
Lina M ObeidDepartment of Medicine, Stony Brook University, Stony Brook, NY, United States of America.
Yusuf A HannunDepartment of Medicine, Stony Brook University, Stony Brook, NY, United States of America.
Michael V AirolaDepartment of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, United States of America.
Cungui MaoDepartment of Medicine, Stony Brook University, Stony Brook, NY, United States of America.ORCID 0000-0002-1330-1887
Stony Brook University · US

Funding

Sphingolipids in Cancer Therapy and AngiogenesisP01CA097132 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI YUSUF AWNI HANNUN · 2003 to 2026
$30.8M
Structure and regulation of lipid metabolism and transportR35GM128666 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Michael Virgil Airola · 2018 to 2026
$4.0M
The Role of Ceramidases in Cancer ChemotherapyR01CA163825 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI MAO, CUNGUI · 2012 to 2016
$1.6M
Role for Sphingosine Kinase 1 in Serine DeprivationR01GM130878 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI MAO, CUNGUI · 2018 to 2020
$1.0M
NCI NIH HHS P01 CA097132NCI NIH HHS R01 CA163825NIGMS NIH HHS R01 GM130878NIGMS NIH HHS R35 GM128666
6 · The paper itself

Abstract

Human alkaline ceramidase 3 (ACER3) is one of three alkaline ceramidases (ACERs) that catalyze the conversion of ceramide to sphingosine. ACERs are members of the CREST superfamily of integral-membrane hydrolases. All CREST members conserve a set of three Histidine, one Aspartate, and one Serine residue. Although the structure of ACER3 was recently reported, catalytic roles for these residues have not been biochemically tested. Here, we use ACER3 as a prototype enzyme to gain insight into this unique class of enzymes. Recombinant ACER3 was expressed in yeast mutant cells that lack endogenous ceramidase activity, and microsomes were used for biochemical characterization. Six-point mutants of the conserved CREST motif were developed that form a Zn-binding active site based on a recent crystal structure of human ACER3. Five point mutants completely lost their activity, with the exception of S77A, which showed a 600-fold decrease compared with the wild-type enzyme. The activity of S77C mutant was pH sensitive, with neutral pH partially recovering ACER3 activity. This suggested a role for S77 in stabilizing the oxyanion of the transition state. Together, these data indicate that ACER3 is a Zn2+-dependent amidase that catalyzes hydrolysis of ceramides via a similar mechanism to other soluble Zn-based amidases. Consistent with this notion, ACER3 was specifically inhibited by trichostatin A, a strong zinc chelator.

Indexed as

Alkaline CeramidaseCeramidesAmidohydrolasesCeramidasesHumansHydrolysisZincAlkaline CeramidaseAmidohydrolasesCeramidasesCeramidesZinc

Identifiers

PMID36048828
PMCPMC9436119
OpenAlexW4294127568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.